Comprehensive Dermatologic Drug Therapy

Part I: Introduction

1. Basic Principles of Pharmacology

2. Principles for Maximizing the Safety of Dermatologic Drug Therapy

3. Polymorphisms: Why Individual Drug Responses Vary

4. Adherence to Drug Therapy

5. Medical Decision Making

Part II: Important Drug Regulatory Issues

6. The FDA Drug Approval Process

7. Pharmacovigilance: Verifying that Drugs Remain Safe

8. Drugs Taken Off the Market: Important Lessons Learned

Part III: Systemic Drugs for Infectious Diseases

9. Systemic Antibacterial Agents

10. Systemic Antifungal Agents

11. Systemic Antiviral Agents

12. Systemic Antiparasitic Agents

Part IV: Systemic Immunomodulatory Drugs

13. Systemic Corticosteroids

14. Methotrexate

15. Azathioprine

16. Mycophenolates

17. Cyclosporine

18. Phosphodiesterase-4 and Janus Kinase Inhibitors

19. Cytotoxic Agents

20. Dapsone

21. Antimalarial Agents

22. Systemic Retinoids

Part V: Drugs Used in Conjunction with UV or Visible Light

23. Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities

24. Extracorporeal Photochemotherapy (Photopheresis)

25. Photodynamic Therapy

Part VI: Biologic Therapeutics

26. Tumor Necrosis Factor Inhibitors

27. Interleukin 12/23 Inhibitors

28. Interleukin 17 Inhibitors

29. Interleukin 23 Inhibitors

30. Rituximab

31. Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others

Part VII: Miscellaneous Systemic Drugs

32. Antihistamines

33. Vasoactive and Antiplatelet Agents

34. Antiandrogens and Androgen Inhibitors

35. Psychotropic Agents

36. Intravenous Immunoglobulin Therapy

37. Systemic Anticancer Agents: Dermatologic Indications and Adverse Events

38. Hedgehog Pathway Inhibitors

39. Drugs for the Skinternist

40. Miscellaneous Systemic Drugs

Part VIII: Topical Drugs for Infectious Diseases

41. Topical Antibacterial Agents

42. Topical Antifungal Agents

43. Topical and Intralesional Antiviral Agents

44. Topical Antiparasitic Agents

Part IX: Topical Immunomodulatory Drugs

45. Topical Corticosteroids

46. Topical Retinoids

47. Topical and Intralesional Chemotherapeutic Agents

48. Topical Calcineurin Inhibitors

49. Topical Vitamin D3

Part X: Miscellaneous Topical Drugs

50. Sunscreens

51. Therapeutic Shampoos

52. α-Hydroxy Acids

53. Chemical Peels

54. Products for the Care of Chronic Wounds

55. Agents Used for Treatment of Hyperkeratosis

56. Irritants and Allergens: When to Suspect Topical Therapeutic Agents

57. Miscellaneous Topical Agents

Part XI: Injectable and Mucosal Routes of Drug Administration

58. Local Anesthetics

59. Injectable Dermal and Subcutaneous Fillers

60. Botulinum Toxin Injections

61. Oral Mucosal Therapeutics

Part XII: Major Adverse Effects From Systemic Drugs

62. Hepatotoxicity of Dermatologic Drug Therapy

63. Hematologic Toxicity of Drug Therapy

64. Drug-induced Malignancy

65. Dermatologic Drugs During Pregnancy and Lactation

66. Drug Interactions

67. Cutaneous Drug Reactions With Systemic Features

Part XIII: Special Pharmacology and Therapeutics Topics

68. Informed Consent and Risk Management

69. Compounding in Dermatology

70. Dermatologic Drug Therapy in Children

Appendix
I Core Questions for Understanding Systemic Dermatologic Drugs
II The Most Potentially Serious Drug Interactions